{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-245815","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.158503+00:00","generated_at":"2026-06-10T07:43:05.405825+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant Prices $280M Public Offering; Roivant Commits $170M Private Placement","bullets":["Public offering of 7,370,000 shares at $38.00/share; gross proceeds ~$280.1M.","Roivant Sciences, majority stockholder, to purchase 4,473,684 shares at same price; proceeds ~$170M.","Combined gross proceeds ~$450M before expenses; expected closing October 2, 2023.","Underwriters granted 30-day option to buy up to 1,105,500 additional shares.","Private placement exempt from registration under Section 4(a)(2) of Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-245815","json":"https://secwatch.observer/filing/0001193125-23-245815.json","markdown":"https://secwatch.observer/filing/0001193125-23-245815.md","text":"https://secwatch.observer/filing/0001193125-23-245815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/0001193125-23-245815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/d555888d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:43:05.405825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bf5dda34d93e82bd4bd02b26c821f9abbf7caa7","claim":"Immunovant, Inc. entered into Purchase Agreement with Roivant Sciences, Ltd. valued at approximately $170,000,000 (effective 2023-09-26).","evidence_excerpt":"On September 26, 2023, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Roivant Sciences, Ltd. (“RSL”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/0001193125-23-245815-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Roivant Sciences, Ltd."},{"label":"Value","value":"approximately $170,000,000"},{"label":"Effective","value":"2023-09-26"}],"fact_type":"material_agreement"},{"claim_id":"907b60cf921e147cd91560e46e90d70d284c900c","claim":"Immunovant, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters valued at approximately $280,060,000 (effective 2023-09-27).","evidence_excerpt":"On September 27, 2023, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives (the “Representatives”) of the underwriters listed on Schedule A thereto, relating to the issuance and sale in an underwritten public offering (the “Public Offering”) by the Company of 7,370,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a public offering price of $38.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/0001193125-23-245815-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters"},{"label":"Value","value":"approximately $280,060,000"},{"label":"Effective","value":"2023-09-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}